Transparent expectation-setting and addressing potential disappointments can foster safety, reduce anxiety, and promote ...

DelveInsight’s, “ Small Lymphocytic Lymphoma Pipeline Insight, 2025 ” report provides comprehensive insights about 80+ ...

Cabometyx® is the first and only systemic therapy to be approved in the European Union for previously treated unresectable or ...

Contract research organizations are reporting better-than-expected second-quarter profit, a sign that Wall Street analysts say reflects a rebound in biotech and pharmaceutical spending after a ...

In what is being hailed as a “groundbreaking achievement” for Uruguay and South America, a weight loss drug has successfully ...

Viking Therapeutics VKTX reported second-quarter 2025 loss of 58 cents per share, wider than the Zacks Consensus Estimate of a loss of 44 cents. The company had incurred a loss of 20 cents per share ...

TherVacB, a therapeutic vaccine for chronic hepatitis B, has entered its first clinical trial in patients. The first patient was enrolled in June 2025 and treated with the vaccine. In a previous trial ...

Durham-based TruTechnologies has secured a strategic growth investment from LLR Partners to accelerate the expansion of its real-time clinical trial oversight solutions and fuel the next phase of ...

Researchers who conducted a real-world analysis of trastuzumab deruxtecan found the drug to be effective in treating metastatic breast cancer, though survival outcomes did not reach clinical trial ...

Loss per share was $(0.58), falling short of analyst expectations by $(0.13), or 29.1% (GAAP, Q2 2025). - Research and development expenses rose to $60.2 million in Q2 2025, up from $23.8 million in ...

Viking Therapeutics, Inc. ( NASDAQ: VKTX) Q2 2025 Earnings Conference Call July 23, 2025 4:30 PM ET Brian Lian - President, CEO & Director Gregory Zante - Chief Financial Officer ...

Research and development collaboration program to include additional models of lymphoma and leukemia to further validate ...